Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types
暂无分享,去创建一个
G. Colditz | C. Vachon | D. Serie | R. Vij | M. Tomasson | A. Gramolini | X. Wen | S. Amend | P. Liu | J. O’Neal | K. Weilbaecher | L. Chu | Lan Lu | M. Hurchla | X. Su | Dingyan Wang | Yalin Xu | W. C. Wilson | Pengyuan Liu
[1] Thomas W. Mühleisen,et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. , 2014, Blood.
[2] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[3] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[4] R. Kyle,et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. , 2011, Blood.
[5] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[6] S. Beer-Hammer,et al. Immunoinhibitory Adapter Protein Src Homology Domain 3 Lymphocyte Protein 2 (SLy2) Regulates Actin Dynamics and B Cell Spreading* , 2011, The Journal of Biological Chemistry.
[7] B. Barlogie,et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.
[8] Arthur S Slutsky,et al. Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1 , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] Rafael Fonseca,et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.
[10] Allan S. Brett,et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance , 2006 .
[11] Terry M Therneau,et al. Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.
[12] R. Hoover,et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. , 2005, Blood.
[13] A. Zallone,et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. , 2004, Blood.
[14] Yuan-Xiao Zhu,et al. The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades , 2004, The Journal of experimental medicine.
[15] Gonzalez,et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.
[16] H. V. van Vlijmen,et al. Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)* , 2003, The Journal of Biological Chemistry.
[17] Yuan-Xiao Zhu,et al. HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells , 2001, Oncogene.
[18] G. Mundy,et al. A murine model of human myeloma bone disease. , 1997, Bone.
[19] J. Radl,et al. Idiopathic paraproteinaemia. I. Studies in an animal model--the ageing C57BL/KaLwRij mouse. , 1978, Clinical and experimental immunology.
[20] J. Epstein,et al. The SCID-hu myeloma model. , 2005, Methods in molecular medicine.
[21] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..